CKD-702 / Chong Kun Dang - LARVOL DELTA

CKD-702, a novel bispecific antibody, enhances anti-tumor effect of combination with EGFR TKIs in NSCLC preclinical model (AACR 2025) - "A Phase I study of CKD-702, which began in 2020, is currently ongoing. Current clinical trials of CKD-702 monotherapy show promising results, with combination therapy being considered to address resistance mechanisms in NSCLC."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Chong Kun Dang's anti-cancer bispecific antibody 'CKD-702' phase 1 clinical trial to be completed next month [Goolge translation] (News1 Korea) - "Chong Kun Dang...is accelerating the development of 'CKD-702', an anti-cancer bispecific antibody that is expected to overcome the limitations of existing lung cancer treatments. Phase 1 clinical trials are expected to be completed in May....After completing the phase 1 clinical trial of CKD-702, Chong Kun Dang plans to conduct global clinical trials by expanding the scope of application to include stomach cancer, colon cancer, and liver cancer."

Trial completion date • Non Small Cell Lung Cancer

[Exclusive] Chong Kun Dang, selection and focus on new drug research and development…Pipeline Tuning [Google translation] (Money Today Network (MTN)) - "Chong Kun Dang recently started adjusting its new drug pipeline to focus on new drug R&D capabilities....According to the industry on the 18th, Chong Kun Dang decided to discontinue R&D...'CKD-516', a colorectal cancer treatment, in the first quarter....In the future, Chong Kun Dang is expected to focus its research capabilities on...'CKD-702', an anti-cancer bispecific antibody biologic."

Discontinued • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

CKD-702 Plus Irinotecan in Gastric Cancer (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: National Cancer Center, Korea

New P2 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • EGFR

A phase I study of CKD-702, an EGFR-cMET bispecific antibody, in advanced or metastatic non-small cell lung cancer (NSCLC) (ESMO 2022) - P1 | "Conclusions CKD-702 has a manageable safety profile related to EGFR and cMet inhibition, and showed preliminary response in patients with MET ex14 skipping. Part 2 (dose expansion) will use IV CKD-702 20 mg/kg q2w; the planned cohort includes MET-alteration NSCLC."

P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy (clinicaltrials.gov) - P1; N=74; Recruiting; Sponsor: Chong Kun Dang Pharmaceutical

Clinical • New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

[VIRTUAL] Anti-tumor efficacy of CKD-702 in EGFR TKI-resistant patient-derived xenograft model (AACR-II 2020) - "% TGI of CKD-702 20mg / kg group was similar to Hu8c4 group or Hu8c4 + Vectibix group. Our data showed that CKD-702 have effective anti-tumor activity in EGFR TKI-resistant PDX model harboring both activating EGFR mutation and c-MET overexpression."

Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • EGFR • MET

[VIRTUAL] The novel bi-specific antibody CKD-702 is a potential agent for NSCLC patients with aberrant cMET and EGFR signaling (AACR-II 2020) - "It is tetravalent IgG1-like bispecific antibody, in which single-chain variable fragment specific to EGFR is genetically fused to the c-terminus of a conventional IgG1 of a cMET. Interestingly, unlike other previously developed EGFR-targeting agents, CKD-702 showed limited skin rash in GLP toxicity study.In summary, CKD-702 is confirmed to inhibit tumors with activated cMET pathway such as cMET amplification and exon 14 skipping as well as with EGFR-activating mutations. This profile of preclinical data supports the clinical trial of CKD-702 as monotherapy in selected lung cancer patients with aberrant cMET and EGFR signaling.A Phase I study of CKD-702 is planned to initiate in 2020."

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer

Chong Kun Dang’s bispecific antibody effective in TKI-resistant animal models (The Korea Herald) - "South Korea’s Chong Kun Dang presented its latest study results of the bispecific antibody pipeline CKD-702 that simultaneously inhibits c-Met and epidermal growth factor (EGFR) in animals who have grown resistant to existing tyrosine kinase inhibitors, at the online American Association of Cancer Research Annual Meeting 2020 that kicked off Monday...CKD-702 showed efficacy in animal models that have grown resistant to existing tyrosine kinase inhibitors..."

Preclinical • Oncology